#NEWS: Transformative results for our investigational medicine will be shared at the 2024 World Conference on Lung Cancer, for patients with HER2-mutated Non-Small Cell Lung Cancer and who have received prior systemic therapy.  Learn more: bitly.cx/Ni1b5

Major effort from the lab (💪Robert Frömel), finally on biorxiv: We built 60,000 fully synthetic enhancers and measured their cell state specific activity during blood stem cell differentiation. Why did we do that and what did we learn🧵? biorxiv.org/content/10.110…

My Top 10 Breast Cancer Abstracts list at #ESMO24 👇

A new GFH375/ VS-7375 preclinical data, presented by Verastem Oncology CSO Jonathan Pachter with GenFleet! #KRAS G12D 🎯 Phase1 study in 🇨🇳, soon in 🇺🇸! LARVOL Cancer Data etc Daniel Gerlach Darryl B McConnell Vivek Subbiah, MD Howard Crawford Simona Cristea Jash Datta, MD Alfredo Addeo MD Jacob J. Adashek, DO

RAS -ON inhibition overcomes clinical resistance to KRAS G12C -OFF covalent blockade. 🔻 doi.org/10.1038/s41467…

RAS-ON inhibition overcomes clinical resistance to KRAS G12C-OFF covalent blockade | Nature Communications nature.com/articles/s4146…

Applications for the EMBL International PhD Programme are open! 👀 The programme offers fully funded PhD positions at EMBL’s six sites across Europe 🌍 Have a look at this opportunity to start your career in the life sciences here: embl.org/about/info/emb…

Our latest publication online now! rdcu.be/dSvhN Nature Communications Amazing team work Santamaria Lab Marie-Julie Nokin Biagio Ricciuti, MD PhD Mark Awad Ernest Nadal Cereda Lab

Schrödinger’s Michael Trzoss presenting the discovery story of their #MALT1 inhibitor enabled by physics-based computational design. Quite impressive the small number of synthesized compounds, though this efficiency is biased by the fast-follower nature of the program #EFMCISMC24

In DB04/06, T-DXd showed similar activity for MBC across HER2 IHC groups Could a more sensitive assay better predict the activity of T-DXd? At #ESMO24 we will present the first data of T-DXd prediction with #HSHER2, which provides the quantitative amount of HER2 in attomols/mm2

Excited to co-organize the virtual EACR Boehringer Ingelheim Conference: Drugging & Regulating the MAP Kinase Pathway! Submit an abstract or join us. Please RT and share with others. Details & registration: eacr.org/conference/boe…

Mechanisms of resistance to #KRAS G12C inhibitors in KRAS G12C-mutated non-small cell lung cancer 🫁 #NSCLC 🔻 doi.org/10.3389/fonc.2…

👉 Already registered for the ESMO Congress 2024? Delegates can view and download the contents of the Virtual Congress Bag.🌐 Get your congress bag today! #ESMO24 🔗 ow.ly/akGU50TggFh

Frontiers | Mechanisms of resistance to KRASG12C inhibitors in KRASG12C-mutated non-small cell lung cancer frontiersin.org/journals/oncol…

D3S-001, a KRAS G12C Inhibitor with Rapid Target Engagement Kinetics, Overcomes Nucleotide Cycling, and Demonstrates Robust Preclinical and Clinical Activities | Cancer Discovery | American Association for Cancer Research aacrjournals.org/cancerdiscover…

KRAS G12D degrader by Astellas to be presented at #ESMO24. ORR at 300mg 33%, MTD not reached

Interesting data with TROP2 quantitative continuous scoring (QCS) to predict the activity of Dato-DXd in lung cancer.

In lung cancer, we know the importance of detecting and targeting MET exon 14 skipping mutations, MET amplification, and MET fusions. Here, we describe another important molecular target: activating MET tyrosine kinase domain (TKD) mutations. #LCSM aacrjournals.org/cancerdiscover…

New drugs ESMO2024

Excited to share our study in Cell on expanding the druggability of GTPases beyond K-Ras and start putting the entire family (150+ proteins) on the map of drug discovery! Kevan Shokat UC San Francisco UCSF Helen Diller Family Comprehensive Cancer Ctr HHMI (1/7) cell.com/cell/fulltext/…